SK Capital Completes Acquisition of Halo Pharmaceutical
January 08, 2015
SK Capital Partners has taken a controlling stake in Halo Pharmaceutical. Founded in 2008 and operating out of facilities in the U.S. and Canada, Halo is a tech-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, applying a particular focus to controlled substances. The transaction marks the sixth platform investment out of SK Capital Partners Fund III, a $500 million vehicle that closed in 2011.